CLINICAL TRIALS PROFILE FOR SCENESSE
✉ Email this page to a colleague
All Clinical Trials for SCENESSE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05159752 ↗ | A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) | Recruiting | Clinuvel Europe Limited | Phase 2 | 2021-10-19 | The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment. |
| NCT05370235 ↗ | A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V | Recruiting | Clinuvel Europe Limited | Phase 2 | 2022-03-28 | The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment. |
| NCT06109649 ↗ | A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo | Recruiting | Clinuvel, Inc. | Phase 3 | 2023-10-11 | The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SCENESSE
Condition Name
Clinical Trial Locations for SCENESSE
Trials by Country
Clinical Trial Progress for SCENESSE
Clinical Trial Phase
Clinical Trial Sponsors for SCENESSE
Sponsor Name
